Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prospero homeobox protein 2 (PROX2) is a DNA-binding transcription factor and member of the homeobox protein family, predicted to regulate transcription by RNA polymerase II in a sequence-specific manner[2][7]. It is a paralog of PROX1 and is involved in developmental processes as a cell fate determinant[1][2]. In model organisms, loss of PROX2 appears dispensable for embryonic development and postnatal survival, with expression reported in postnatal eye, adult testes, and embryos, but no clear essential or disease-driving functions in humans have been confirmed[1][2][7]. Disease associations are limited, primarily reported with atrial septal defect[2], and there are currently no known drugs, biomarkers, or established therapeutic targeting of PROX2.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prospero homeobox protein 2 (PROX2).